Given these data, ser-miR-21 could be a potential biomarker to predict clinical response to neoadjuvant chemotherapy combined with trastuzumab, but it may also serve as a prognostic marker in HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.